Morgan Lewis

Life Sciences Protecting the Complete Life Cycle

For More Information

Read the Brochure

Life Sciences and Healthcare

Life Sciences Deskbook

New Resource

New Resource: Health Industry Transparency Compliance Resource Center

Emerging Business Tools

visit the Entrepreneur Resource Headquarters

Practice Highlights

Honors

PLCCross-border Quarterly 2012 Life Sciences Legal Market Review

  • Life Sciences Regulatory Super League - Ranked 8th among law firms worldwide

PLCCross-border Life Sciences Handbook 2011/12

  • U.S.:
    • Commercial and Partnering - Highly Recommended
    • Competition/Antitrust - Highly Recommended
    • Corporate - Recommended
    • Government Enforcement and Investigations - Highly Recommended
    • Regulatory - Recommended
    • Regulatory (Medical Devices) - Recommended
  • England: Regulatory - Recommended
  • Japan: Corporate and Commercial - Recommended

Chambers Global 2011: Global Life Sciences - Recommended - Band 3

Chambers USA 2011: National for Life Sciences - Band 3; Washington, D.C. for healthcare/ pharmaceutical/ medical products regulatory - Band 3

UK Legal 500 2010: London: Pharmaceuticals and Biotechnology

Best Lawyers in America 2011: Biotechnology and Healthcare Law Named

BioPharm Insight 2011

  • Ranked 3rd - Global League Table of Legal Advisers on Licensing Agreements - Based upon Volume
  • Ranked 6th - Global League Table of Legal Advisers on Licensing Agreements - Based upon Value
  • Ranked 4th - League Table of Legal Advisers on North American Licensing Agreements - Based upon Volume
  • Ranked 9th - League Table of Legal Advisers on North American Licensing Agreements - Based upon Value
  • Ranked 3rd - League Table of Legal Advisers on European Licensing Agreements - Based upon Volume
  • Ranked 4th - League Table of Legal Advisers on European Licensing Agreements - Based upon Value
  • Ranked 2nd - League Table of Legal Advisers on Asia-Pacific Licensing Agreements - Based upon Volume
  • Ranked 5th - League Table of Legal Advisers on Asia-Pacific Licensing Agreements - Based upon Value
U.S. News & World Report/Best Lawyers 2010: Ranked Tier 1 National Practice - Biotechnology

Clients

16 of the top 20 pharmaceutical companies

7 of the top 20 biotechnology companies

9 of the top 20 medical device companies

Related Events

06/06/12-06/08/12 ABA’s Civil False Claims Act and Qui Tam Enforcement 2012
Katie McDermott, presenter, "Investigation of a False Claims Act Case"
06/06/12-06/07/12 2012 Health Law Institute in Minneapolis
Arianne Callender, speaker, "Fraud and Abuse Update"
06/09/12-06/12/12 The Business of Medicine 2012 San Diego Summit
Kathleen McDermott, presenter, "Shining a Light on the Sunshine Act: What You Need To Know"
View all events

Related News

05/04/12 Regulatory Policy: CBER Importance Boosted With Attention To Biologic Drugs, Biosimilars, Speakers Say
Life Sciences and Healthcare partner Stephen Paul Mahinka is quoted.
04/25/12 Q&A With Morgan Lewis' Randall Sunberg, Law360
Business and Finance partner Randall Sunberg is interviewed as part of Law360 's Q&A series.
04/05/12 Biosimilars Naming and Labeling: An FDLI Dialogue, Update Magazine
Life Sciences and Healthcare partner Stephen Paul Mahinka is quoted.
View all news

Related Publications

05/09/12 Eleventh Circuit Rejects FTC Challenge to Reverse Payment Settlement
Decision by court of appeals affirms that settlements that do not expand the exclusionary scope of a patent are not subject to antitrust challenge.
05/03/12 HHS Plugs Payment Suspensions as Key Tool in Latest Takedown
The Medicare Fraud Strike Force's use of a pivotal ACA regulation to suspend payments during criminal investigations signals a turning point in its prosecution strategy.
View all publications

With more than 200 lawyers, scientists and other technical specialists who focus on the life sciences industry, we have one of the most comprehensive practices of any U.S. law firm. Unlike other law firms, we understand the scientific, business, and regulatory issues that our clients face and have expanded our practice to include more than 60 professionals with advanced life sciences degrees.

Our clients include many of the largest and most successful pharmaceutical companies in the world, as well as a long list of biotechnology companies, medical device manufacturers, nutritional companies, healthcare providers, renowned research and scientific institutions, and life sciences-focused investment banks and venture capital firms. As diverse as they are, these companies share a common need for comprehensive, integrated legal services that address all of the business issues and opportunities facing the industry.

Having expressly developed our capabilities to cover seamlessly the complete life sciences product lifecycle, we offer an unsurpassed mix of services that are critical to this industry. Our Life Sciences practice focuses on all important areas, from transactions and litigation to regulatory approvals and compliance and protection of intellectual property, as well as key supporting capabilities, including FDA and healthcare, patents and patent litigation, labor and employment law, Morgan Lewis Resources workplace training and immigration, and antitrust. As a full-service firm with offices in the financial and regulatory centers of central importance to the industry in the U.S., Europe and Asia, we are uniquely situated to provide counseling for the full range of business activities.